Browsing by Author "Bahl, Ankur"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    A case of primary rectal non-Hodgkin's lymphoma treated with chemotherapy.
    (2008-10-28) Singla, Rajiv; Kumar, Pradeep; Bahl, Ankur; Kumar, Suresh; Saran, Ravindra Kumar; Kar, Premashish
    Primary rectal non-Hodgkin's lymphoma is a rare disease. Surgery has been proposed as the primary treatment modality for colorectal lymphomas. We report a case of rectal non-Hodgkin's lymphoma (B cell large cell type, Ann Arbor Stage 1E) who responded completely to systemic chemotherapy.
  • Thumbnail Image
    Item
    The growing menace of fake counterfeit and substandard medicines from across our borders
    (Scientific Scholar, 2018-09) Kulkarni, Padmaj; Gulia, Ashish; Bhosale, Bharatsingh; K, Govind Babu; T Raja; Bahl, Ankur; Talwar, Vineet; Chairman, Ashok Vaid
  • Thumbnail Image
    Item
    A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone杛eleasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix)
    (Wolters Kluwer - Medknow, 2022-03) Bahl, Ankur; Rajappa, Senthil; Rawal, Sudhir; Bakshi, Ganesh; Murthy, Vedang; Patil, Ketaki
    Luteinizing hormone杛eleasing hormone agonist (LHRH?A), goserelin, and antagonist, degarelix, are both indicated for the treatment of advanced prostate cancer (PCa); however, large comparative trials evaluating their efficacy and safety are lacking. In this review, we assessed the available evidence for both the drugs. Although degarelix achieves an early rapid decline in testosterone (T) and prostate?specific antigen (PSA) levels, median T and PSA levels, in addition to prostate volume and International Prostate Symptom Scores, become comparable with goserelin over the remaining treatment period. Degarelix causes no initial flare, therefore it is recommended in patients with spinal metastases or ureteric obstruction. Goserelin achieves lower PSA, improved time to progression, and better survival outcomes when administered adjunctively to radiotherapy compared with radiotherapy alone, with significant results even over long?term follow?up. The evidence supporting adjuvant degarelix use is limited. Goserelin has better injection site safety, single?step delivery, and an efficient administration schedule compared with degarelix, which has significantly higher injection site reactions and less efficient administration mechanism. There is conflicting evidence about the risk of cardiovascular disease (CVD), and caution is required when using LHRH?A in patients with preexisting CVD. There is considerable long?term evidence for goserelin in patients with advanced PCa, with degarelix being a more recent option. The available comparative evidence of goserelin versus degarelix has several inherent limitations related to study design, sample size, conduct, and statistical analyses, and hence warrants robust prospective trials and long?term follow?up.